M. Clearfield et al., Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): baseline characteristics and comparison with USA population, J CARD RISK, 7(2), 2000, pp. 125-133
Background Results of the Air Force/Texas Coronary Atherosclerosis Preventi
on Study (AFCAPS/TexCAPS) demonstrated that treatment with lovastatin, in a
ddition to modifications of diet and lifestyle, reduced the rate of first a
cute major coronary events compared with placebo in a cohort that included
participants with average to mildly elevated total levels of cholesterol, a
nd below average levels of high-density lipoprotein cholesterol, women, and
elderly subjects.
Objective To describe the baseline characteristics of the study's cohort.
Design This was a double-blind, placebo-controlled, primary-prevention tria
l in which Americans with average to mildly elevated total levels of choles
terol [4.65-6.83 mmol/l (180-264 mg/dl)] and no clinical evidence of athero
sclerotic cardiovascular disease were randomly allocated either 20-40 mg/da
y lovastatin or placebo in addition to a low-saturated fat, low-cholesterol
diet. Baseline characteristics of the study cohort are described, and the
characteristics of a USA reference population based upon NHANES III data ar
e provided for comparison.
Results The study includes 5608 men (85%) and 997 women (15%) with mean tot
al cholesterol level 5.71 +/- 0.54 mmol/l (221 +/- 21 mg/dl), low-density l
ipoprotein cholesterol level 3.88 +/- 0.44 mmol/l (150 +/- 17 mg/dl), high-
density lipoprotein cholesterol 0.96 +/- 0.15 mmol/l (37 +/- 6 mg/dl), and
median triglyceride level 1.78 +/- 0.86 mmol/l (158 +/- 76 mg/dl). The mean
age is 58 years (ranges 45-73 years for men and 55-73 years for women), Th
e participants are 89% white, 7% Hispanic, and 3% black.
Conclusion Results from AFGAPS/TexCAPS will be applicable to large segments
of populations; in the USA alone, eight million share the demographic and
baseline-lipid-level characteristics of the study cohort. J Cardiovasc Risk
7:125-133 (C) 2000 Lippincott Williams & Wilkins.